|

bleximenib Clinical Trials

3 actively recruiting trials across 2 locations

No change since May 2026

Also known as: JNJ-75276617

Pipeline

Phase 1: 1Phase 3: 2

Top Sponsors

  • Janssen Research & Development, LLC2
  • Stichting Hemato-Oncologie voor Volwassenen Nederland1

Indications

  • Cancer3
  • Acute Myeloid Leukemia2
  • Acute Leukemias1
  • Leukemia, Myeloid, Acute1
  • Acute Lymphoblastic Leukemia1

Other1 trial

A Study of 14C-Bleximenib (Radiolabeled) in Participants With Acute Leukemia
Phase 1

Birmingham, Alabama1 trial

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

University of Alabama at Birmingham

Phase 3

Cincinnati, Ohio1 trial

Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)

US-Cincinnati OH-CINCY

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.